SPONSORS
EHMSG gratefully acknowledges the support of the following companies
RICHEN EUROPE is the European operating branch of the RICHEN GROUP, a major international group of medical device manufacturers with a global commitment. The company specializes in developing the best solutions for patients in the field of gastroenterology. Over the years our R&D department has excelled in the design and development of high-performance safe equipment and reagents for the diagnosis of Helicobacter pylori infection. Since 2015, the Richen Group has been supporting the European Helicobacter & Microbiota Study Group (EHMSG) as Platinum Sponsor.
INFAI is specialized in the transfer of advanced analytical technology in the field of medical diagnostics and the development of innovative pharmaceutical products. The company is a pioneer in the use of stable isotopes in gastroenterology, cardiovascular and inborn metabolic diseases. Helicobacter Test INFAI (HTI) is approved in centralized procedure by EMA first time in all European countries since 1997 and available for routine diagnosis of Helicobacter pylori infection. In the meantime, HTI is registered as medicinal product (medical prescription) in more than 40 countries worldwide.
INFAI's laboratories in Bochum, Germany and in York, England are equipped with state-of-the-art IRMS mass spectrometer and 600 MHz NMR spectrometer which is used to investigate metabolic disorders, cardiovascular diseases and a number of other diseases. These facilities are used for internal research and product development, but are also available for collaborative and contract research. In last 10 years, a range of non-invasive, highly efficient breath tests using stable isotopes has been developed. Gastromotal (13C octanoic acid gastric emptying test) and Pancreo-Lip (13C mixed triglyceride exocrine pancreatic function test) are in preparation for approval by EMA but now available for clinical studies. INFAI is associated with a number of companies in several European countries and outside the Europe. All other developed products of INFAI you can find on our website: https://www.infai1.com
Since 1997, INFAI GmbH has been supporting the European Helicobacter & Microbiota Study Group (EHMSG) as Gold Sponsor.
In 2016 Mayoly Spindler acquired Kibion – the world leader in fast and reliable urea breath testing machines and tests for the diagnosis and eradication control of Helicobacter pylori for the diagnosis and control of the eradication of this bacterium.
In 2019 Mayoly Spindler created the new business unit Mayoly Diagnostic.
As a strategic pillar of the development of our company this business unit is dedicated to the marketing of analytical systems, consumables and drugs for the diagnosis and eradication control of Helicobacter pylori.
American Molecular Laboratories Located in Chicago IL USA, is a biotech company that specializes in molecular diagnostics. Our PyloriDx™/PyloriAR™ H. Pylori detection and antibiotic resistance Next Generation Sequencing panel is the most comprehensive assay of its kind in the world. This assay tests all major genes in the H. pylori genome for variants that are associated with antibiotic resistance to six common antibiotics used in treatment. Three specimen types are accepted: FFPE tissue, fresh tissue, and stool. PyloriAR™ has >99% accuracy and can assist clinicians determining a course of treatment for high-risk patients, patients who were treated for H. pylori and reinfected, and patients with a H. pylori diagnosis that aren’t improving with their current treatment.
Biocodex is a family-owned pharmaceutical company that has grown from a French microbiota pioneer in the 1950s to an international pharmaceutical player today by diversifying its products and expanding its geographical footprint. We offer health solutions to patients in more than 120 countries through our own operations or long-term partnerships. We are proud of our teams, who are united by shared values. These serve as driving forces, enabling us to grow while remaining agile.
BIOHIT HealthCare Ltd, based in North West England, is the UK subsidiary of BIOHIT Oyj, a Finnish biotechnology company specialising in the development, manufacture and marketing of products and analysis systems for the early diagnosis and prevention of gastrointestinal diseases.
We specialise in digestive disease diagnostics, offering a portfolio of unique and patented tests designed to transform clinical practice by making screening, diagnosis and monitoring of gastrointestinal diseases more efficient and cost effective. Non-invasive diagnostics are at the core of our offering, making BIOHIT HealthCare the provider of choice for leading gastroenterologists and laboratory scientists across the UK. URL: https://biohithealthcare.co.uk
For over 60 years, Dr Falk Pharma GmbH, an independent family company has maintained a strong international reputation for the development and production of products that treat digestive and metabolic diseases. Innovation drives everything we do. As specialists in digestive and metabolic medicine, we bring physicians, scientists, and patients together to develop new and powerful approaches to patient care. We continuously listen to your needs and respond with treatment solutions that provide real improvement to patients’ health and well-being. As a research-based family business with global presence, our aim is to help transform clinical practice, one life-changing discovery at a time. URL: www.drfalkpharma.com
Meridian is a fully integrated life science company that develops, manufactures, markets, and distributes a broad range of innovative diagnostic and life science products. We are dedicated to developing and delivering better solutions that give answers with speed, accuracy, and simplicity that are redefining the possibilities of life from discovery to diagnosis.
Phathom Pharmaceuticals is a late clinical-stage biopharmaceutical company focused on developing and commercializing new treatments for GI disorders. We have licensed the exclusive rights in the United States, Europe, and Canada to vonoprazan, an investigational potassium competitive acid blocker (P-CAB) in late clinical-stage development for the treatment of gastric acid-related disorders.
Waldner Tecnologie Medicali S.r.l.
Founded in 1997, Waldner operates in the market for the sale and commercial consultancy of medical products and systems. Waldner brings innovation and new technologies to the gastroenterology segment, through Endofaster which represents a new approach to gastroscopy dedicated to professionals in the sector. Endofaster is the first device that analyzes data in real time, favoring greater diagnostic accuracy and the possibility of performing gastroscopy with a totally new approach.
URL: https://waldner.it/
Voted Best UK Convention Bureau for the last 15 years, Glasgow’s experienced conventions team continuously develops its city wide strategic partnerships, world leading Conference Ambassador Programme and bespoke public engagement activities to support UK, European and international clients with hosting a successful and memorable meeting in Glasgow.